<DOC>
	<DOC>NCT00515593</DOC>
	<brief_summary>The objectives of the study are - to describe the quality of life at the beginning of the Preotact® treatment and at the end of the observational period (Qualeffo-41 questionnaire) - pain assessment at the beginning of the Preotact® treatment and at the end of the observational period (VAS score) - to describe bone mineral density at the beginning of the Preotact® treatment and at the end of the observational period (T-Score) - to describe incidence of bone fractures caused by osteoporosis as well as of other pathological findings of the skeleton after the beginning of the Preotact® treatment - to describe serum level of calcium and the bone resorption marker desoxypyridinoline (DPD) and N- respectively C-terminal crosslink-telopeptide (CTX and NTX) at the beginning of the Preotact® treatment and at the end of the observational period (only in subgroup of patients, where the physician sees a need to measure these parameters) - to document all adverse drug reactions after the beginning of the Preotact® treatment - the analysis of subgroups with different risk for bone fractures caused by osteoporosis at the beginning of the Preotact® treatment - to assess the manageability and functioning of the Pen system for injection of Preotact® (self administered questionnaire)</brief_summary>
	<brief_title>PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Inclusion requires that Preotact® is prescribed in accordance with the SPC and that the stated contraindications are strictly considered. Caution should be taken by the treating Physician concerning any precautions, warnings and potential drug interactions stated in the SPC. No further inclusion or exclusion parameters are defined. The decision for the individual application of Preotact® will be strictly made by the physicians.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal women</keyword>
	<keyword>Severe postmenopausal osteoporosis</keyword>
</DOC>